Tocilizumab

證據等級: L5

預測適應症: 10 個

Tocilizumab: From Rheumatoid Arthritis to Ankylosing Spondylitis

One-Sentence Summary

Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody originally developed for rheumatoid arthritis (and later juvenile idiopathic arthritis). The TxGNN model predicts it may be effective for Ankylosing Spondylitis, with a very high similarity score, but 9 clinical trials and 19 publications in the evidence pack show that this hypothesis has already been directly tested — and the two pivotal Phase III trials were terminated for lack of efficacy.

Quick Overview

Item	Content
Original Indication	Rheumatoid Arthritis (no structured license data available; confirmed by literature within this evidence pack, e.g. PMID 19368420, 28841363)
Predicted New Indication	Ankylosing Spondylitis
TxGNN Prediction Score	99.99%
Evidence Level	L1 (Phase II/III RCT-level evidence — negative result)
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed structured mechanism-of-action data is not available for this drug (data gap). Based on the literature contained in this evidence pack, tocilizumab is a humanized monoclonal antibody that blocks the interleukin-6 receptor (IL-6R), inhibiting IL-6-mediated pro-inflammatory signaling. Its efficacy is well established for rheumatoid arthritis and juvenile idiopathic arthritis (confirmed elsewhere in this same evidence pack by pivotal trials such as NCT00988221, NCT00144625 and NCT00144664).

IL-6 is an acute-phase, pro-inflammatory cytokine that is also elevated with disease activity in ankylosing spondylitis (AS), which is why AS was historically considered a plausible extension of IL-6R blockade from RA. The very high TxGNN score likely reflects the close topological similarity between RA and AS as inflammatory joint diseases in the knowledge graph.

However, the evidence pack's own mechanistic assessment flags an important caveat: unlike RA, the dominant pathogenic axis in AS/axial spondyloarthritis is IL-17/IL-23–Th17 signaling rather than IL-6. This is precisely the mechanistic background behind the clinical failure of IL-6R antagonists (both tocilizumab and sarilumab) in AS. Two dedicated Phase II/III placebo-controlled RCTs — NCT01209702 (n=306) and NCT01209689 (n=113) — were both terminated due to lack of efficacy, and these results were subsequently published (PMID 23765873, BUILDER-1/2). This is real, direct negative clinical evidence rather than an absence of evidence, so despite the model's high prediction score, the repurposing hypothesis is not supported.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01209702	Phase 2/3	Terminated	306	Placebo-controlled RCT of tocilizumab 8 mg/kg IV q4w in NSAID-refractory, TNF-naïve AS patients — terminated for lack of efficacy
NCT01209689	Phase 3	Terminated	113	Placebo-controlled RCT of tocilizumab (4 or 8 mg/kg IV) in AS patients with inadequate response to prior TNF antagonists — terminated for lack of efficacy
NCT05696106	N/A	Unknown	750,000	Large registry study of incident immune-mediated inflammatory disease risk in biologic-treated patients; not AS-efficacy specific
NCT01965132	N/A	Recruiting	10,000	Korean nationwide biologics/tsDMARD registry covering RA, AS and PsA safety; observational, no efficacy hypothesis
NCT05670301	N/A	Recruiting	2,500	Cytokine/biomarker profiling across systemic inflammatory diseases; not an AS treatment trial
NCT02569736	N/A	Completed	60	Mechanistic study of tocilizumab effect on T follicular helper cells in RA patients; not AS-specific
NCT07138898	Phase 2	Not yet recruiting	80	Perioperative immunosuppressant management in general rheumatology patients undergoing shoulder arthroplasty; not AS-efficacy specific
NCT02925338	N/A	Completed	1,431	Real-world observational registry — note: evaluates infliximab (Inflectra), not tocilizumab
NCT07477795	Phase 2	Not yet recruiting	52	Secukinumab in Takayasu arteritis — different drug and disease, low relevance

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23765873	2014	RCT	Ann Rheum Dis	BUILDER-1/2 RCTs assessing short-term symptomatic efficacy and safety of tocilizumab in AS
26986130	2016	Systematic Review / Network Meta-analysis	Medicine	Comparative effectiveness of all available biologic regimens for AS
29290076	2018	Meta-analysis (Cohort)	Clin Rheumatol	Risk of serious infections with biologics in AS and non-radiographic axial SpA
28413099	2017	Review	Semin Arthritis Rheum	Second-line biologic therapy optimization in RA, PsA and AS
22452603	2012	Review	Inflamm Allergy Drug Targets	Short review specifically on antagonizing IL-6 in AS
21803631	2011	Review	Joint Bone Spine	Biologic agents for AS beyond TNFα antagonists
22450391	2012	Review	Curr Opin Rheumatol	Treatment options for AS refractory to TNF inhibition
19822066	2009	Review	Clin Exp Rheumatol	Biologics in the treatment of RA and AS
29278210	2017	Review	Curr Pharm Biotechnol	Biologics in inflammatory and immunomediated arthritis, including AS
33981717	2021	Case Report	Front Med	Two cases of successful treatment of AA amyloidosis secondary to AS using tocilizumab

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Two dedicated Phase II/III placebo-controlled RCTs of tocilizumab in ankylosing spondylitis (NCT01209702, NCT01209689) were both terminated for lack of efficacy, and this is consistent with the mechanistic rationale in the evidence pack — AS pathogenesis is driven primarily by the IL-17/IL-23–Th17 axis rather than IL-6. This is direct negative clinical evidence, not merely insufficient evidence, so this specific repurposing candidate should not advance.

To proceed, the following is needed:

TFDA/BfArM package insert (warnings, contraindications) — currently a Blocking data gap (DG001), required before any S1 safety evaluation of tocilizumab for any indication
Structured mechanism-of-action data from DrugBank API — High-priority data gap (DG002)
If repurposing exploration continues for this drug, prioritize other candidates in this evidence pack with more favorable (or at least non-negative) evidence profiles, such as rheumatoid vasculitis (L4, flagged as "Research Question" rather than "Hold"), over further work on the AS hypothesis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.